Wang Lijuan, Zeng Zhaopie, Emmons Gary
Drug Disposition, DSAR, sanofi-aventis, JR2-203B, Bridgewater, NJ 08807, USA. lijuan.wang @sanofi-aventis.com
Bioanalysis. 2010 Aug;2(8):1365-71. doi: 10.4155/bio.10.100.
The dried blood spots (DBS) technique has been actively evaluated as plasma replacement for monitoring drug exposure to support drug development in preclinical/clinical pharmacokinetic and toxicokinetic studies. Plasma samples from some of these studies are typically used for metabolite profiling and identification and for determination of disproportionate metabolites between safety species and humans to address metabolites in safety testing issues. The objectives of this study were to explore the feasibility of using the DBS technique for a metabolism study and to compare metabolite radioprofiles between DBS, plasma and whole blood samples.
The radioactivity extraction recovery in DBS samples was similar or better than that in plasma or whole blood. The metabolite radioprofiles in AUC pooled DBS samples using FTA(®) and FTA(®) Elute cards were comparable to those in AUC pooled plasma and whole blood.
It is feasible to use DBS as an alternative matrix to plasma for in vivo metabolite radioprofiling studies for SA-1.
干血斑(DBS)技术已被积极评估作为血浆替代物,用于监测药物暴露,以支持临床前/临床药代动力学和毒代动力学研究中的药物开发。这些研究中的一些血浆样本通常用于代谢物谱分析和鉴定,以及确定安全物种与人类之间不成比例的代谢物,以解决安全性测试中的代谢物问题。本研究的目的是探索使用DBS技术进行代谢研究的可行性,并比较DBS、血浆和全血样本之间的代谢物放射性谱。
DBS样本中的放射性提取回收率与血浆或全血中的相似或更好。使用FTA(®)和FTA(®)洗脱卡的AUC合并DBS样本中的代谢物放射性谱与AUC合并血浆和全血中的相当。
使用DBS作为血浆的替代基质用于SA-1的体内代谢物放射性谱研究是可行的。